Prevention and NHS screening programmes

Screening is a programme, not simply a test. It identifies an eligible population, issues proactive invitations, uses a defined initial test, provides quality assurance, confirms positive results, offers treatment or surveillance and monitors outcomes. The UK National Screening Committee assesses the entire pathway for evidence that benefit exceeds harm, including acceptability, feasibility and equity. A sensitive test without effective follow-up or beneficial treatment does not make a good programme.

The person invited is usually apparently well. Participation is voluntary and requires balanced information. Potential benefits include earlier treatment and reduced disease-specific mortality or morbidity. Harms include false reassurance after a false negative, anxiety and procedures after a false positive, overdiagnosis of disease that would never have caused harm, overtreatment and opportunity costs. Presenting screening as compulsory or guaranteed prevention invalidates informed choice.

Screening and diagnosis answer different questions. Screening estimates risk in an asymptomatic eligible group. Diagnostic assessment investigates symptoms, signs or a known high-risk condition. Rectal bleeding, a breast lump, postcoital bleeding or a pulsatile abdominal mass must be assessed through the appropriate clinical pathway regardless of age, invitation status or a recent negative screen. Do not order a screening test as a shortcut for a symptomatic patient when the diagnostic threshold and test differ.

Programme details differ across England, Scotland, Wales and Northern Ireland. The exact ages stated here describe England on 7 September 2026. Clinicians working elsewhere must use their national programme. Invitations depend on accurate GP registration, demographic coding and contact details. Gender markers, organ inventory, previous surgery, relocation, homelessness and digital exclusion can create silent omissions; practices should use inclusive recall systems and individual review.

Cervical screening in England invites eligible women and people with a cervix from age 25 to 64 every five years. HPV primary screening permits a longer routine interval after a negative result; HPV positivity or cell changes lead to earlier testing or colposcopy under programme protocols. A person without a cervix after total hysterectomy may not need routine screening, but the indication and previous histology determine follow-up. Symptoms require assessment rather than waiting for screening.

Bowel cancer screening in England offers a faecal immunochemical test every two years to people aged 50 to 74 who are registered with a GP. People aged 75 or over can request a kit every two years. FIT detects human haemoglobin and a programme-positive result leads to further assessment, commonly colonoscopy when appropriate. A negative screening FIT does not exclude cancer in a symptomatic person, and a diagnostic FIT result must be managed under the symptomatic pathway.

Breast screening invites women for a first mammogram between 50 and 53, then every three years until the 71st birthday. Those aged 71 or over can request screening every three years. Registration records affect automatic invitation for trans and non-binary people, so discuss anatomy, treatment and local service access sensitively. A new breast lump, skin tethering, unilateral nipple change or other concern needs clinical assessment and must not await the next mammogram.

AAA screening in England offers a one-off abdominal ultrasound to people registered as male with a GP during the screening year in which they turn 65. Older men who have not been screened can self-refer. The result enters a defined surveillance or referral pathway based on aortic diameter. Women and younger men are not routinely invited because population benefit-harm differs, but suspected aneurysm or a strong individual clinical indication belongs to diagnostic care.

Diabetic eye screening is surveillance within a national programme. Everyone with diabetes aged 12 or over is invited. In England, people whose last two routine screens found no diabetic retinopathy can be invited every two years; others receive more frequent screening according to findings. This does not replace routine optometry or urgent ophthalmic assessment for sudden visual loss, painful red eye, flashes, floaters or other symptoms.

The NHS Lung Cancer Screening Programme is being rolled out in England. Current and former smokers aged 55 to 74 are invited for a risk assessment in participating areas; people assessed at high risk are offered low-dose CT. Implementation remains geographically staged, so use current local eligibility and invitation arrangements. Respiratory symptoms require diagnostic assessment and smoking cessation support should be offered regardless of screening eligibility.

The NHS Health Check is a prevention and risk-assessment programme in England, generally offered every five years to eligible adults aged 40 to 74 without specified pre-existing vascular conditions. It is distinct from nationally managed screening programmes but uses systematic invitation to identify cardiovascular and related risk. Act on results using current NICE pathways and support smoking cessation, physical activity, diet, alcohol reduction and weight goals through shared decisions.